Asset Details
Do you wish to reserve the book?
Rifabutin loaded inhalable β-glucan microparticle based drug delivery system for pulmonary TB
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rifabutin loaded inhalable β-glucan microparticle based drug delivery system for pulmonary TB
Do you wish to request the book?
Rifabutin loaded inhalable β-glucan microparticle based drug delivery system for pulmonary TB
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rifabutin loaded inhalable β-glucan microparticle based drug delivery system for pulmonary TB
2024
Overview
Inhalable microparticle-based anti TB drug delivery systems are being investigated extensively for Tuberculosis [TB] treatment as they offer efficient and deep lung deposition with several advantages over conventional routes. It can reduce the drug dose, treatment duration and toxic effects and optimize the drug bioavailability. Yeast derived β-glucan is a β-[1–3/1–6] linked biocompatible polymer and used as carrier for various biomolecules. Due to presence of glucan chains, particulate glucans act as PAMP and thereby gets internalized via receptor mediated phagocytosis by the macrophages. In this study, β-glucan microparticles were prepared by adding l-leucine as excipient, and exhibited 70% drug [Rifabutin] loading efficiency. Further, the sizing and SEM data of particles revealed a size of 2–4 µm with spherical dimensions. The FTIR and HPLC data confirmed the β-glucan composition and drug encapsulations efficiency of the particles. The mass median aerodynamic diameter [MMAD] and geometric standard deviation [GSD] data indicated that these particles are inhalable in nature and have better thermal stability as per DSC thermogram. These particles were found to be non-toxic upto a concentration of 80 µg/ml and were found to be readily phagocytosed by human macrophage cells in-vitro as well as in-vivo by lung alveolar macrophage. This study provides a framework for future design of inhalable β-glucan particle based host-directed drug delivery system against pulmonary TB.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/250
/ 631/326
/ 631/45
/ 639/301
/ 639/925
/ 692/308
/ 692/699
/ Alveoli
/ Antitubercular Agents - administration & dosage
/ Antitubercular Agents - chemistry
/ Antitubercular Agents - pharmacokinetics
/ Glucans
/ Humanities and Social Sciences
/ Humans
/ Leucine
/ Polymers
/ Rifabutin - administration & dosage
/ Rifabutin - pharmacokinetics
/ Science
/ Tuberculosis, Pulmonary - drug therapy
/ Yeast
/ β-Glucan
